Treatments for Alcoholic Hepatitis are Not Reducing Mortality Rates
New NASH Treatment Could Be Available in the Near Future
New Fatty Liver Drug to Inhibit the Production and Retention of Fat
Learn about aramchol, an up and coming drug to treat advanced stage fatty liver disease.
Galmed Pharmaceuticals Ltd (GLMD) Works to Treat Advanced-Stage Fatty Liver Disease with Aramchol Drug
Galmed Pharmaceuticals Ltd (GLMD) CFO Josh Blacher says that in clinical studies its product candidate aramchol has displayed significant activity in reducing liver fat concentration. This reduction may be critical in patients suffering from NASH, or nonalcoholic steatohepatitis.
“It’s our belief, based on our research and scientific literature, that the excessive fat is in fact the root cause of the liver’s deterioration,” Blacher says. “As such, we believe that if you can inhibit the production and accumulation of liver fat, you prevent the domino effect of the inflammation. So that’s in fact what we are aiming to do, and that is our mechanism of action: to inhibit the production and retention of liver fat.”
Continue reading this entire article: